Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes Mellitus

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Overweight or Obesity, Type2 Diabetes Mellitus

In brief

This study will evaluate safety, tolerability, pharmacokinetic (PK) profile, and pharmacodynamic (PD) effects on GSBR-1290 in healthy overweight/obese volunteers (HOV) and Type 2 Diabetes Mellitus on Metformin (T2DM) This study includes 5 planned cohorts. Participants will receive multiple-ascending doses of GSBR-1290 or Placebo from Day 1 to Day 84

Key facts

Study ID
NCT05762471
Run by
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
People needed
142
Starts
2023-01-09
Expected to finish
2024-04-11
Last updated by the study team
2024-04-25

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.